Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PAVmed ( (PAVM) ) has issued an update.
On December 5, 2025, PAVmed Inc. held a special meeting where stockholders approved an amendment to the company’s certificate of incorporation. This amendment allows for a reverse stock split at a ratio between 1-for-10 and 1-for-30, and a reduction in authorized common stock from 250 million to 25 million shares. The board of directors has yet to decide the specific ratio for the reverse split but plans to implement the changes soon by filing with the Delaware Secretary of State.
The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
PAVmed’s overall stock score is primarily impacted by its financial challenges, including persistent losses and negative cash flows. Technical indicators show a bearish trend, and valuation metrics are weak due to unprofitability. The earnings call provided some positive strategic updates, but ongoing challenges in revenue growth and debt restructuring remain significant concerns.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
Average Trading Volume: 493,993
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.12M
Find detailed analytics on PAVM stock on TipRanks’ Stock Analysis page.